Welcome to our dedicated page for Scilex Holding Company SEC filings (Ticker: SCLXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company SEC filings page for the warrant symbol SCLXW provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Scilex’s common stock (SCLX) and its warrants to purchase common stock at an exercise price of $402.50 per share (SCLXW) are listed on The Nasdaq Stock Market LLC, and the company identifies itself as an emerging growth company in its reports.
Through forms such as Form 10-K, Form 10-Q, and Form S-1, Scilex describes its business of acquiring, developing, and commercializing non-opioid pain management products, including commercial products ZTlido ae, ELYXYB ae, and Gloperba ae, and product candidates SP-102, SP-103, and SP-104. The registration statement on Form S-1 specifically addresses aspects of the company’s warrants and related securities offerings.
Current reports on Form 8-K give detail on material events that may be relevant to SCLXW holders, such as warrant exchange agreements, new warrant issuances, equity lines of credit, and options to repurchase previously issued warrants. For example, Scilex has reported a Common Stock Purchase Agreement with an institutional investor, Warrant Exchange Agreements that modify existing warrant terms, and an option agreement with Oramed Pharmaceuticals Inc. to repurchase penny warrants. Other 8-K filings discuss Semnur Pharmaceuticals, Inc.’s merger agreement with Denali Capital Acquisition Corp. and changes in executive leadership.
These filings also disclose Scilex’s collaborations and licensing arrangements, including a worldwide exclusive license from Datavault AI Inc. for AI-driven tokenization technology in biotech and biopharma, and strategic investments in Datavault AI. Such agreements can influence Scilex’s long-term business model and potential revenue sources, and are documented in detail in the underlying exhibits and narrative sections.
On Stock Titan, investors can use AI-powered tools to review Scilex’s 10-K annual reports, 10-Q quarterly reports, S-1 registration statements, and 8-K current reports. AI-generated summaries help explain complex capital structure terms for SCLXW, highlight key risk factors and business descriptions, and surface notable items such as warrant terms, exchange ratios, and major financing arrangements, while real-time updates ensure new EDGAR filings are reflected promptly.
Scilex Holding Company disclosed changes in executive status and debtor-in-possession (DIP) financing arrangements. Dr. Ji is referenced in connection with a decision to resign as Chief Executive Officer and President to focus on Semnur, while the filing also states his compensation was not changed upon appointment as CEO and President and that he entered an indemnification agreement. The filing compares terms of a Junior DIP Loan (higher interest and fees: 14.0% vs 12.0%, maturity 5 vs 3 months, commitment/funding fees 2.5% vs 1.0%, exit fee 7.0% vs 2.0%). It describes a $100,000,000 Replacement DIP Facility provided by Oramed Pharmaceuticals, which refinanced the Senior DIP and included milestones and a lender credit-bid right for collateral (including equity interests). The Purchase Price for certain assets included a cash payment of $10,000,000 and assumption of approximately $12.25 million in legal fees; Sorrento retained 54,777 common shares in abeyance. A Pay-Off Letter would terminate the Junior DIP Loan Agreement and related security agreements upon Closing.
Oramed Pharmaceuticals Inc. filed an amendment to Schedule 13G disclosing beneficial ownership of 764,277 shares of Scilex Holding Co. common stock, representing 9.9% of the class. The filing clarifies that 762,277 of these shares are issuable upon exercise of warrants exercisable within 60 days of the filing date and that the total percent calculation used 6,955,697 outstanding shares reported by the issuer. Oramed reports sole voting and dispositive power over all 764,277 shares. The filing states the holdings were not acquired to change or influence control.
Scilex Holding Company is a revenue-generating, non-opioid pain-management company that commercializes ZTlido, ELYXYB and GLOPERBA and is developing SP-102, SP-103 and SP-104. For the quarter ended June 30, 2025 the Company reported net revenue of $9.9 million and for the six months a net loss of $70.1 million, driven by an operating loss of $48.4 million and large non-cash fair value and derivative losses.
Balance sheet highlights show $4.1 million in cash, total assets of $83.8 million, total liabilities of $332.7 million and total stockholders' deficit of $(249.0) million. Management disclosed substantial doubt about the Company’s ability to continue as a going concern for one year and identified a negative working capital position of $272.3 million. Material items include a $43.8 million deemed dividend from a 1-for-35 reverse split that increased loss attributable to common shareholders, $20.3 million of derivative warrant liabilities, significant accrued rebates and fees of $192.9 million, and concentrated customer exposure (four customers represented 99% of revenue).
Scilex Holding Company filed Prospectus Supplement No. 2 (Rule 424(b)(3)) on 24 June 2025 to incorporate its Form 8-K dated 23 June 2025. The supplement registers (a) up to 1,594,207 shares of common stock for resale by existing security-holders, (b) up to 198,810 shares issuable from the exercise of 1,402,955 SPAC warrants, and (c) the resale of those 1,402,955 private placement warrants themselves. Each SPAC warrant, adjusted for the 15 April 2025 1-for-35 reverse stock split, now entitles the holder to purchase 1⁄35 of a share at an exercise price of $402.50 per whole share. The company receives no proceeds from share resales but would receive cash upon warrant exercises. On 23 June 2025 the stock closed at $4.98 (ticker SCLX) and the public warrant at $0.0855 (ticker SCLXW).
The accompanying Form 8-K reports results of the 20 June 2025 Annual Meeting. Quorum was achieved with 100 % of Series A Preferred Stock (29,057,097 shares) and 67.3 % of Common Stock (4,678,182 of 6,951,622 shares) present or represented. Holders voted on an as-converted basis, providing 922,447 aggregate votes from the preferred shares. Directors Jaisim Shah (3,537,589 for / 323,203 withheld) and Henry Ji, Ph.D. (3,433,624 for / 427,168 withheld) were re-elected as Class III directors through 2028. BPM LLP was ratified as independent auditor for fiscal 2025 (5,354,958 for / 166,743 against / 78,928 abstain).
The prospectus supplement must be read together with the May 13 2025 base prospectus and includes customary risk-factor references. No other financial statements or earnings data were provided.
FAQ
What is the current stock price of Scilex Holding Company (SCLXW)?
